Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Allowance for U.S. Patent that Covers the Company’s differentiated assay for the diagnosis of thyroid cancer Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that...
Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on March 17, 2017 Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by...
Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces the...
Reiterates 2017 RosettaGX Reveal revenue guidance of between $4 million and $5 million as Company increases focus on the Reveal market opportunity Rosetta Genomics Ltd. (NASDAQ:ROSG), a...
Strengthens the Intellectual Property Surrounding the Company’s Novel Thyroid Nodule Classifier and Provides Opportunities for IP Monetization Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic...
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, today announced it has entered into definitive...
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into a research agreement with...
Second peer-reviewed publication represents a major milestone that is expected to support continued RosettaGX Reveal momentum Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and...
Previously available online, print article enhances awareness of the first commercial test validated to analyze the same thyroid cells on which the initial indeterminate diagnosis was based...
Brings extensive molecular diagnostic commercial and market access leadership to drive revenue and expand reimbursement across portfolio of high-value assays Company expects to build on...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 9.9E-5 | 9900 | 1.0E-6 | 0.0001 | 1.0E-6 | 60 | 0.0001 | CS |
| 26 | 0 | 0 | 0.0001 | 0.0001 | 1.0E-6 | 48 | 4.239E-5 | CS |
| 52 | 0 | 0 | 0.0001 | 0.0001 | 1.0E-6 | 1128 | 9.817E-5 | CS |
| 156 | -0.0015 | -93.75 | 0.0016 | 0.0018 | 1.0E-6 | 4976 | 0.00035268 | CS |
| 260 | -0.0031 | -96.875 | 0.0032 | 0.39 | 1.0E-6 | 22868 | 0.07237317 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| SPRVSupurva Healthcare Group Inc (PK) | US$ 0,0001 (-50,00%) | 163,23M |
| ASIIAccredited Solutions Inc (PK) | US$ 0,0006 (33,33%) | 152,19M |
| CBGLCannabis Global Inc (PK) | US$ 0,0001 (100,00%) | 149,39M |
| GRLFGreen Leaf Innovations Inc (PK) | US$ 0,0001 (0,00%) | 118,61M |
| ABQQAB International Group Corporation (PK) | US$ 0,0011 (10,00%) | 103,11M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
